MM 302

Drug Profile

MM 302

Alternative Names: Nano-doxorubicin

Latest Information Update: 10 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator HERMES BioSciences
  • Developer Merrimack Pharmaceuticals
  • Class Antineoplastics; Doxorubicins; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA intercalators; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Breast cancer

Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 01 Mar 2017 Discontinued - Phase-II for Breast cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Austria, Canada, France, Germany, Spain, Belgium, Italy, USA (IV) (Merrimack Pharmaceuticals 10-K, March 2017)
  • 08 Jan 2017 MM 302 is available for licensing as of 08 Jan 2017. www.merrimack.com
  • 21 Dec 2016 Merrimack Pharmaceuticals terminates the phase II HERMIONE trial in Breast cancer due to the inability of MM 302 to demonstrate benefit over the comparator treatments
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top